JPWO2020112937A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020112937A5 JPWO2020112937A5 JP2021530887A JP2021530887A JPWO2020112937A5 JP WO2020112937 A5 JPWO2020112937 A5 JP WO2020112937A5 JP 2021530887 A JP2021530887 A JP 2021530887A JP 2021530887 A JP2021530887 A JP 2021530887A JP WO2020112937 A5 JPWO2020112937 A5 JP WO2020112937A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- sulfur
- oxygen
- compound
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 93
- 150000001875 compounds Chemical class 0.000 claims description 69
- 229910052757 nitrogen Inorganic materials 0.000 claims description 68
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 62
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 62
- 229910052760 oxygen Inorganic materials 0.000 claims description 62
- 239000001301 oxygen Chemical group 0.000 claims description 62
- 239000011593 sulfur Chemical group 0.000 claims description 62
- 229910052717 sulfur Chemical group 0.000 claims description 62
- 125000005842 heteroatom Chemical group 0.000 claims description 60
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 43
- 229920006395 saturated elastomer Polymers 0.000 claims description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 208000035475 disorder Diseases 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- 125000002950 monocyclic group Chemical group 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 10
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000017701 Endocrine disease Diseases 0.000 claims description 6
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims description 6
- 208000030172 endocrine system disease Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010066946 Craniofacial dysostosis Diseases 0.000 claims description 2
- 201000006526 Crouzon syndrome Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 102000002227 Interferon Type I Human genes 0.000 claims description 2
- 108010014726 Interferon Type I Proteins 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Chemical group 0.000 claims description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 239000010703 silicon Chemical group 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024120957A JP2024160253A (ja) | 2018-11-30 | 2024-07-26 | Ｔｙｋ２阻害剤およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773620P | 2018-11-30 | 2018-11-30 | |
| US62/773,620 | 2018-11-30 | ||
| PCT/US2019/063510 WO2020112937A1 (en) | 2018-11-30 | 2019-11-27 | Tyk2 inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120957A Division JP2024160253A (ja) | 2018-11-30 | 2024-07-26 | Ｔｙｋ２阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022509260A JP2022509260A (ja) | 2022-01-20 |
| JPWO2020112937A5 true JPWO2020112937A5 (enExample) | 2022-12-05 |
| JP7530360B2 JP7530360B2 (ja) | 2024-08-07 |
Family
ID=70848642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530887A Active JP7530360B2 (ja) | 2018-11-30 | 2019-11-27 | Ｔｙｋ２阻害剤およびその使用 |
| JP2024120957A Pending JP2024160253A (ja) | 2018-11-30 | 2024-07-26 | Ｔｙｋ２阻害剤およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024120957A Pending JP2024160253A (ja) | 2018-11-30 | 2024-07-26 | Ｔｙｋ２阻害剤およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11053241B2 (enExample) |
| EP (1) | EP3886843A4 (enExample) |
| JP (2) | JP7530360B2 (enExample) |
| CN (1) | CN113271938A (enExample) |
| AU (1) | AU2019389025B2 (enExample) |
| CA (1) | CA3120866A1 (enExample) |
| IL (1) | IL283409A (enExample) |
| WO (1) | WO2020112937A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017040757A1 (en) | 2015-09-02 | 2017-03-09 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2018075937A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| US11414431B2 (en) | 2018-10-15 | 2022-08-16 | Nimbus Lakshmi, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors |
| CN113271938A (zh) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| CN116635377A (zh) * | 2020-12-25 | 2023-08-22 | 四川海思科制药有限公司 | 己酮糖激酶抑制剂及其用途 |
| US20240246944A1 (en) | 2021-03-16 | 2024-07-25 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| US20250051338A1 (en) | 2021-10-25 | 2025-02-13 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| TW202425965A (zh) * | 2022-09-30 | 2024-07-01 | 日商科研製藥股份有限公司 | 縮環化合物及含有其之醫藥 |
| CN115974751A (zh) * | 2022-12-13 | 2023-04-18 | 山东能源集团新材料有限公司 | 一种吡拉西坦制备方法及系统 |
| AU2023410062A1 (en) * | 2022-12-22 | 2025-08-07 | Protekt Therapeutics Ltd. | Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors |
| WO2025010294A2 (en) * | 2023-07-03 | 2025-01-09 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds and use as tyk2 inhibitors |
| US11878978B1 (en) | 2023-09-06 | 2024-01-23 | King Faisal University | Pyrrolo[2,3-c]quinoline compounds as CK2 inhibitors |
| US11891394B1 (en) | 2023-09-06 | 2024-02-06 | King Faisal University | Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors |
| US11858935B1 (en) | 2023-09-06 | 2024-01-02 | King Faisal University | Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors |
| CN117342955A (zh) * | 2023-10-08 | 2024-01-05 | 盐城师范学院 | 一种制备4’-甲基-联苯-2-胺的方法 |
| WO2025222103A1 (en) * | 2024-04-19 | 2025-10-23 | Raythera, Inc. | Stat6 modulators and methods of uses thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| CN1264381A (zh) | 1997-08-05 | 2000-08-23 | 辉瑞产品公司 | 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药 |
| UA72290C2 (uk) | 1999-12-10 | 2005-02-15 | Пфайзер Продактс Інк. | СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ) |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| EP2055310B1 (en) | 2002-08-14 | 2015-12-16 | Silence Therapeutics GmbH | Protein kinase N beta for the diagnosis and the treatment of late stage tumor |
| BRPI0409063A (pt) | 2003-04-03 | 2006-03-28 | Semafore Pharmaceuticals Inc | pró medicamentos de inibidor de pi-3 cinase |
| BRPI0410870A (pt) | 2003-05-30 | 2006-07-04 | Gemin X Biotechnologies Inc | compostos trieterocìclicos, composições, e métodos para tratar cáncer ou doenças virais |
| CN100577680C (zh) | 2003-07-03 | 2010-01-06 | 宾夕法尼亚大学理事会 | 对Syk激酶表达的抑制 |
| RS55546B1 (sr) | 2004-05-13 | 2017-05-31 | Icos Corp | Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze |
| ATE412651T1 (de) * | 2004-06-09 | 2008-11-15 | Glaxo Group Ltd | Pyrrolopyridinderivate |
| KR20220084426A (ko) | 2004-07-28 | 2022-06-21 | 다케다 야쿠힌 고교 가부시키가이샤 | 피롤로〔2,3-ｃ〕피리딘 화합물, 그 제조 방법 및 용도 |
| EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| KR101533268B1 (ko) | 2005-05-12 | 2015-07-03 | 애브비 바하마스 리미티드 | 아폽토시스 촉진제 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| EP1931645B1 (en) | 2005-10-07 | 2014-07-16 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| DK3184526T3 (en) | 2005-12-13 | 2019-01-14 | Incyte Holdings Corp | PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0710874A2 (pt) | 2006-04-26 | 2012-02-14 | Hoffmann La Roche | compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos |
| PT2201840E (pt) | 2006-09-22 | 2012-02-14 | Pharmacyclics Inc | Inibidores da tirosina quinase de bruton |
| CN101861313B (zh) | 2007-03-12 | 2014-06-04 | Ym生物科学澳大利亚私人有限公司 | 苯基氨基嘧啶化合物及其用途 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| BRPI0909040B8 (pt) | 2008-03-11 | 2021-05-25 | Incyte Holdings Corp | derivados de azetidina e ciclobutano, seus usos, e composição |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TWI620737B (zh) | 2012-11-08 | 2018-04-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| SG10201706897TA (en) | 2012-11-08 | 2017-09-28 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alph responses |
| ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| MX362341B (es) | 2014-05-01 | 2019-01-11 | Novartis Ag | Compuestos y composiciones como agonistas del receptor tipo toll 7. |
| JP7125385B2 (ja) | 2016-08-08 | 2022-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| CN109952303B (zh) * | 2016-10-14 | 2022-10-21 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| EP3538513A1 (en) * | 2016-11-11 | 2019-09-18 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| CN113271938A (zh) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
-
2019
- 2019-11-27 CN CN201980087661.3A patent/CN113271938A/zh active Pending
- 2019-11-27 CA CA3120866A patent/CA3120866A1/en active Pending
- 2019-11-27 EP EP19888308.4A patent/EP3886843A4/en active Pending
- 2019-11-27 AU AU2019389025A patent/AU2019389025B2/en active Active
- 2019-11-27 US US16/697,371 patent/US11053241B2/en active Active
- 2019-11-27 WO PCT/US2019/063510 patent/WO2020112937A1/en not_active Ceased
- 2019-11-27 JP JP2021530887A patent/JP7530360B2/ja active Active
-
2021
- 2021-05-14 US US17/320,394 patent/US11834449B2/en active Active
- 2021-05-24 IL IL283409A patent/IL283409A/en unknown
-
2024
- 2024-07-26 JP JP2024120957A patent/JP2024160253A/ja active Pending